India plans upgrade of device trials rules and regulations in 2015
This article was originally published in Clinica
India's Central Drugs Standard Control Organization (CDSCO) has outlined a list of policy initiatives for 2015, which includes introducing a bill that would amend the current Drugs & Cosmetics Act & Rules and add new provisions for clinical trials and regulation of medical devices.
You may also be interested in...
Wockhardt has received approvals in India for two novel broad spectrum antibiotics with "advantageous" safety features over older MRSA drugs and the firm hopes to take them to other emerging markets as well, with China on the radar.
2019 saw Indian companies advance innovation efforts and build and expand their specialty portfolios and biosimilars businesses. But manufacturing compliance issues weighed down several firms while on another front charges against the Singh brothers of Ranbaxy escalated.
Glenmark is working on a combination of remogliflozin and teneligliptin in India, which if successful could bring additional sting to its portfolio in the country's bustling diabetes segment. But Boehringer-Lilly’s rival Glyxambi already has a head-start.